Widespread use of radiopharmaceutical isotopes with diagnostic equipment such as PET and SPECT systems could buoy the global nuclear medicine/radiopharmaceutical market to $7 billion by the end of the decade.
A new report from MarketsandMarkets projects that the worldwide market could reach $6.96 billion by 2020, compared with $4.5 billion in 2015, for a compound annual growth rate of 9.1%.
In 2014, the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceutical diagnostics market, according to the market research firm.
The cardiology segment was the largest portion of the SPECT market last year, while the oncology segment accounted for the largest share of the PET market.
